Emerging synthetic drugs for the treatment of liver cirrhosis
Jonathan Fallowfield, Maria Jiménez Ramos, Andrew Robertson
Abstract
: Although cirrhosis can regress following successful etiological treatment, there are no specific antifibrotic or pro-regenerative drugs approved for this condition. Obstacles to drug development in cirrhosis include intrinsic biological factors, a heterogeneous patient population, and lack of acceptable surrogate endpoints. Nevertheless, several synthetic drugs are being evaluated in clinical trials and the NASH field is rapidly embracing a drug combination approach.
Topics & Concepts
MedicineCirrhosisLiver transplantationIntensive care medicineClinical trialSteatohepatitisPopulationDrug developmentDrugInternal medicineTransplantationDiseasePharmacologyFatty liverEnvironmental healthLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver physiology and pathology